KLK3 and prostate cancer: During 2016 and 2017, 229 patients with prostate cancer underwent whole-body MRI and 161 patients aged 71 years (IQR 64–76) and with median PSA 13.0 (IQR 8–28) were eligible for analysis (Fig. 1).